Literature DB >> 29582450

Tamper-resistant prescription forms for narcotics in France: Should we generalize them?

Amélie Daveluy1,2, Lucie Sauvaget1, Angela Bastien1, Maryse Lapeyre-Mestre3, Cédric Collin4, Nathalie Richard4, Françoise Haramburu1,2.   

Abstract

In France, prescription of narcotics must be written on a tamper-resistant prescription form with specific technical particularities. Dosage and daily dose of medicines shall be written out entirely in letters. These prescription forms are also mandatory for buprenorphine, clorazepate, clonazepam, tianeptine, buccal midazolam and zolpidem owing to traffic, abuse or diversion. In 2012, to assess the use of standard and tamper-resistant prescription forms and the acceptability of the generalization of the latter to all medicines, a national opinion survey was performed, with a postal questionnaire, within three randomized samples of 1500 prescribers (physicians, dentists and midwives). Of the 403 participating prescribers (participation rate of 26.8%), 373 were physicians, 14 dentists and 16 midwives. Tamper-resistant prescription forms were used by 76.2% of prescribers, but only by 5.1% in a computerized version, whereas for standard prescription forms, 61% used computer assisted prescription software. The main reason was the inability of the prescription software to print these forms or to respect the mandatory prescription rules for narcotics. Theft and falsification of prescriptions had ever occurred (working life). Most prescribers (62.5%) were against the generalization of tamper-resistant prescription forms. Those in favour were for a generalization to all medicines (65%) and not only to psychotropic agents. Generalization of tamper-resistant prescription forms is not a consensual solution to prevent medicines' diversion. Some prescribers alluded to the possibility of dematerialization and electronic transmission of prescription forms, which could avoid theft, forgery or falsification.
© 2018 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  addictovigilance; controlled substances; drug prescriptions; electronic prescribing

Mesh:

Substances:

Year:  2018        PMID: 29582450     DOI: 10.1111/fcp.12368

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  4 in total

1.  Impact of Secured Prescription Implementation for Zolpidem on Hypnotics Use in France: A Time-Series Analysis on National Data.

Authors:  Nicolas Rousselot; Antoine Pariente; Yohann Mansiaux; Caroline Victorri-Vigneau
Journal:  Ann Fam Med       Date:  2020-07       Impact factor: 5.166

2.  A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Authors:  Joelle Perri-Plandé; Ghada Miremont-Salamé; Joëlle Micallef; Cameron Herman; Marie Baumevieille; Frédéric Abriat; Maryse Lapeyre-Mestre; Françoise Haramburu; Amélie Daveluy
Journal:  Drug Saf       Date:  2021-10-29       Impact factor: 5.606

3.  Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior.

Authors:  Edouard-Jules Laforgue; Marion Istvan; Benoit Schreck; Marie Mainguy; Pascale Jolliet; Marie Grall-Bronnec; Caroline Victorri-Vigneau
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

4.  Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review.

Authors:  Gaetan Gentile; Maryse Lapeyre-Mestre; Joelle Micallef
Journal:  BJGP Open       Date:  2020-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.